Update in the management of chronic hepatitis B

Current Opinion in Gastroenterology

Volumn 29, Issue 3, 2013, Pages 250-256

  Tujios, Shannan R ^a   Lee, William M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

antiviral therapy; chronic hepatitis B; chronic liver disease; nucleos(t)ide analogs

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 28B; LAMIVUDINE; PEGINTERFERON; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG MONITORING; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON TYPE I; ORGANOPHOSPHONATES; PRACTICE GUIDELINES AS TOPIC;

EID: 84876285519     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835ff1e9     Document Type: Review

References (35)

1. Wiersma S. The global burden of disease of viral hepatitis. Viral Hepat 2011; 19:9-10.
2. Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis 2012; 16:347-369.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
4. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. Hepatol Int 2012; 6:531-561.
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
6. Papatheodoridis GV, Manolakopoulos S, Liaw YF, et al. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B infection with persistently normal ALT: a systematic review. J Hepatol 2012; 57:196-202.
7. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut 2012; 61:333-336.
8. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low viral load. Gastroenterology 2012; 142:1140-1149.
9. Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143:629.e1-636.e1.
10. Reijnders JG, Perquin MJ, Zhang N, et al. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139:491-498.
11. Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012; 46:865-870.
12. Tseng TC, Liu CJ, Su TH, et al. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012; 206:1521-1531.
13. Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis Be antigen-positive chronic hepatitis B patients receiving pegylated interferon alpha-2a therapy. Antivir Ther 2011; 16:629-637.
14. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142:513.e1-520.e1.
15. Wu X, Xin Z, Zhu X, et al. Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese. Antiviral Res 2012; 93:297-300.
16. Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2012. doi: 10.1002/hep.25749.
17. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotype B or C. Hepatology 2011; 54:1591-1599.
18. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61 (Suppl. 1):i18-i24.
19. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012; 56:1006-1011.
20. Lampertico P, Vigano M, De Costanzo GG, et al. Randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2012; 62:290-298.
21. Chan HL. Peginterferon therapy for chronic hepatitis B: one size fits all? Gut 2013; 62:185-187.
22. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-näive chronic hepatitis B patients. J Hepatol 2012; 57:508-514.
23. Zoutendijk R, Reijnders JG, Zoulim F, et al. Gut 2012. doi: 10.1136/gutjnl-2012-302024.
24. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (in press). doi: 10.1002/hep.26180.
25. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143:619-628.
26. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastro-enterology 2011; 140:132-143.
27. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate treatment for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2012; 381:468-475.
28. Gish RG, Clark MD, Kane SD, et al. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012; 10:941-946.
29. Gish R, Jia JD, Locarnini S, et al. Selection of hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12:341-353.
30. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11-20.
31. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56 (Suppl 1):S112-S122.
32. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56:520-526.
33. Seto WK, Liu K, Fung J, et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther 2012; 17:1255-1262.
34. Zhao P, Wang C, Huang L, et al. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res 2012; 96:100-104.
35. Cho Y, Lee DH, Chung KH, et al. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci 2012. doi 10.1007/s10620-012-2480-1.